Phase III Drugs Slated to Add Additional $30 Billion in Revenues by 2010

New York, March 10, 2006 — With future blockbuster drugs currently in the Phase III pipeline—many on track to be approved in 2006—the potential to add $30 billion to current pharmaceutical market revenues is looking more and more like a reality, according to a study released today from Kalorama Information, a division of MarketResearch.com, a leading provider of industry-specific market research reports.

Leading the pack are new cancer drugs, which according to The Impact of the Phase III Pipeline, could add over $15.5 billion in new revenues to the market. Expected to compete with and provide advanced alternatives to current therapies, these new therapeutics could help to stimulate cancer drugs’ market share to 20% by 2010. Also in the pipeline are a myriad of new neuropsychotherapeutic drugs, most significantly those in the mental illness sector, and cardiovascular drugs, both of which have the potential to add an additional value of $5 billion over the next four years.

“A lot is riding on these drugs for the pharma industry,” notes Steven Heffner, publisher of Kalorama Information. “Not only will these drugs challenge current treatment protocols by providing much needed advancements, but they have the potential to boost consumer confidence in an industry, which has lost favor due to high profile recalls over the last several years.”

Designed to provide industry professionals with a comprehensive profile of current Phase III drugs, this report includes tables and figures in each of the market chapters, which tell the story of the winners, losers, and segments most impacted by the drugs that Kalorama Information predicts will gain approval. Market opportunity revenues are provided for each segment—cardiovascular, neuropsychotherapeutic, infectious disease, cancer, and other drugs such as diabetes, asthma, gastrointestinal, asthma, sexual dysfunction, arthritis and others—for approvals anticipated from 2006 to 2010, with specific information related to 2006 approvals.

The Impact of the Phase III Pipeline, which includes a market overview, descriptions of products in development, and 2006 competitive analysis, can be purchased directly from Kalorama Information by clicking http://www.kaloramainformation.com/pub/1187684.html. It is also available at MarketResearch.com.

About Kalorama Information
Kalorama Information, a division of MarketResearch.com, supplies the latest in independent market research for the life sciences. For more information, contact Tom Ehart at 240-747-3014 or tehart@marketresearch.com, or visit www.KaloramaInformation.com.